Drug Profile
Latanoprost micro-formulation - Eyenovia
Alternative Names: MicroProst; Piezo-print micro-formulated latanoprostLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Eyenovia
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Angle-closure glaucoma
Most Recent Events
- 18 Mar 2021 Phase-II development is ongoing in Panama
- 13 Feb 2019 Eyenovia plans a phase III trial in chronic Angle closure glaucoma, Open angle glaucoma and Ocular hypertension in USA in the end of 2019
- 28 Nov 2018 Efficacy and adverse events data from a phase II trial in Angle-closure glaucoma released by Eyenovia